Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001214659-21-009448
Filing Date
2021-09-13
Accepted
2021-09-13 16:17:24
Documents
64
Period of Report
2021-07-31

Document Format Files

Seq Description Document Type Size
1 p9821110q.htm   iXBRL 10-Q 751936
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 8173
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 8198
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 6063
  Complete submission text file 0001214659-21-009448.txt   4503494

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE alzn-20210731.xsd EX-101.SCH 47696
6 XBRL CALCULATION FILE alzn-20210731_cal.xml EX-101.CAL 38346
7 XBRL DEFINITION FILE alzn-20210731_def.xml EX-101.DEF 212634
8 XBRL LABEL FILE alzn-20210731_lab.xml EX-101.LAB 338010
9 XBRL PRESENTATION FILE alzn-20210731_pre.xml EX-101.PRE 292585
10 EXTRACTED XBRL INSTANCE DOCUMENT p9821110q_htm.xml XML 611685
Mailing Address 3802 SPECTRUM BLVD, SUITE C112C TAMPA FL 33612
Business Address 3802 SPECTRUM BLVD, SUITE C112C TAMPA FL 33612 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-40483 | Film No.: 211249885
SIC: 2834 Pharmaceutical Preparations